INTRODUCTION
============

The oculocardiac reflex (OCR) is a sudden onset bradycardia that occurs sometimes during mechanical manipulation of the eye, eyelids or orbit. The afferent pathway comes from the ophthalmic branch of the trigeminal nerve. The efferent pathway is carried by the vagus nerve, which is accountable for the vagally mediated response of bradycardia \[[@B1]-[@B3]\]. Although sinus bradycardia is the most frequent effect of OCR, arrhythmia and asystole have been reported as well \[[@B4]-[@B7]\]. OCR occurs more frequently in children, especially during strabismus surgery \[[@B8]-[@B11]\] , it can also occur in adults \[[@B12], [@B13]\] and it has been described in a large variety of ophthalmic procedures \[[@B14]-[@B24]\].

The intensity of OCR decreases after repeated stimuli \[[@B25]\]. It is a fatigable reflex. Retrobulbar block \[26\], the use of anticholinergics \[[@B27]-[@B29]\] and deeper general anesthesia \[[@B10], [@B30], [@B31]\] can help reduce the occurrence of OCR. On the other hand, when fast-acting opioids \[[@B32], [@B33]\] or dexmedetomidine \[[@B34], [@B35]\] are used, they can increase OCR.

Intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) \[36-40\] and other drugs \[[@B41]-[@B44]\] is now the most frequent procedure performed in ophthalmology \[[@B45]\]. IVI of anti-VEGF is commonly used to treat a variety of retinal conditions, such as age related macular degeneration and diabetic retinopathy \[[@B39], [@B46]-[@B51]\]. It is estimated that 5.9 million IVI were performed in the United States in 2016 \[[@B45]\].

The purpose of this study was to evaluate OCR during IVI.

MATERIALS and METHODS
=====================

During a 30-day period (June 2019), 532 patients scheduled for IVI were included for this study at the Asociacion para Evitar la Ceguera en Mexico (APEC) in Mexico City. The study complied with the Declaration of Helsinki. A written informed consent was obtained from all patients. This study received an ethical approval from our academic center. Only one eye of each patient was considered for the study. Patients taking medication for arrhythmia or having a pacemaker were excluded, all other patients were included. All injections were performed in the supero-temporal quadrant location. Injections were done following the 2018 consensus protocol recommendations \[[@B43]\]. The IVI was achieved in a sterile fashion ([Figure 1](#F1){ref-type="fig"}). Heart rate was measured with a pulse oximeter (Zacurate, The USA) before and after placing the eyelid speculum, during the injection and after removing the speculum.

![Superotemporal Intravitreal Injection in a Sterile Fashion in the Left Eye](mehdiophth-9-111-g001){#F1}

**Statistical analysis**

The percentage of patients with a decrease of 20% or more in basal heart rate was calculated using programming language R \[[@B52]-[@B54]\].

Results
=======

As shown in [Table 1](#T1){ref-type="table"}, of 532 eyes studied, 262 were males and 270 females, with a mean (range) age of 63.8 (29 -- 89) years and 247 IVI in the right eye (OD) and 285 in the left eye (OS). Indications for IVI were respectively diabetic retinopathy (DR) in 352 eyes, age related macular degeneration (AMD) in 177 and choroidal neovascularization (CNV) secondary to pathological myopia in 3. In terms of the type of drug injected, 340 eyes received Ranibizumab (Lucentis; Genentech, The USA), 186 eyes Aflibercept (Wetlia; Bayer, Germany) and 3 eyes Ozurdex implant by IVI (Allergan, The USA; Dexamethasone intravitreal implant), respectively. Regarding OCR, of 532 patients enrolled, 18 presented a decrease in basal heart rate of 20% or more ([Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}). As shown in [Table 2](#T2){ref-type="table"}, of 18 eyes, 12 were males and 6 females with a mean (range) age of 63.2 (41-84) years and 8 IVI in the OD and 10 IVI in the OS. Indications for IVI in these 18 patients were DR in 10 eyes, AMD in 6 eyes and CNV secondary to pathological myopia in 2 eyes. Ranibizumab was injected in 10 eyes and Aflibercept in 8 eyes. Statistical analysis showed a 3.3% incidence for OCR during IVI. A 95% confidence interval (CI) was found to be (1.85% and 4.92%). However, all patients with OCR were asymptomatic.

###### 

Demographic Characteristics of the Study Subjects

  Age; range (years)       29 -- 89 (mean 63.8)   
  ------------------------ ---------------------- -----
  Gender; n                Male                   262
  Female                   270                    
  Laterality; n            OD                     247
  OS                       285                    
  Indication for IVI; n    DR                     352
  AMD                      177                    
  CNV                      3                      
  Injected Medication; n   Ranibizumab            340
  Aflibercept              186                    
  Ozurdex                  3                      

Abbreviations: n: number of eyes; OD: right eye; OS: left eye; IVI: intravitreal injection; DR: Diabetic Retinopathy; AMD: age related macular degeneration; CNV: choroidal neovascularization secondary to secondary to pathological myopia; Ranibizumab: Lucentis (Genentech, The USA); Aflibercept: Wetlia (Bayer, Germany); Ozurdex: (Allergan, The USA) Dexamethasone intravitreal implant.

###### 

A Summary of Characteristics of Patients With OCR During IVI

  No.   Sex; F/M   Age; Y   Basal HR   IVI HR   Name of Medication   Side   Diagnosis
  ----- ---------- -------- ---------- -------- -------------------- ------ -----------
  1     F          55       86         63       Aflibercept          OD     DR
  2     F          84       91         69       Ranibizumab          OS     DR
  3     F          63       89         65       Aflibercept          OD     DR
  4     F          60       75         57       Aflibercept          OD     AMD
  5     F          50       92         73       Aflibercept          OS     DR
  6     F          59       85         65       Ranibizumab          OS     DR
  7     M          76       92         64       Aflibercept          OS     AMD
  8     M          41       95         75       Ranibizumab          OD     CNV
  9     M          56       105        82       Ranibizumab          OD     DR
  10    M          62       89         69       Ranibizumab          OD     DR
  11    M          64       86         66       Aflibercept          OS     DR
  12    M          54       89         68       Ranibizumab          OS     DR
  13    M          60       99         66       Ranibizumab          OS     CNV
  14    M          77       81         62       Aflibercept          OD     AMD
  15    M          74       63         49       Ranibizumab          OS     AMD
  16    M          65       84         58       Aflibercept          OS     DR
  17    M          71       73         57       Ranibizumab          OD     AMD
  18    M          67       82         61       Ranibizumab          OS     AMD

Abbreviations: F: female; M: male; Y: years; HR: heart rate; IVI: intravitreal injection; OD: right eye; OS: left eye; DR: Diabetic Retinopathy; AMD: age related macular degeneration; CNV: choroidal neovascularization secondary to pathological myopia; Ranibizumab: Lucentis (Genentech, USA); Aflibercept: Wetlia (Bayer, Germany).

DISCUSSION
==========

In this study, OCR occurred in 3.3% of patients during IVI. All patients who had OCR were asymptomatic. OCR occurred in patients of both genders and all were over 40 years. OCR occurred with both Aflibercept and Ranibizumab, both were the most frequent medications used in this study.

OCR is more common in children, particularly during strabismus surgery, although other studies have shown that OCR can occur in adults \[[@B13]\]. Using electrocardiogram, in 1998 we published a series of adult patients with OCR during Laser-Assisted In Situ Keratomileusis (LASIK) \[[@B13]\]. In patients with OCR, decrease in heart rate appeared when the suction ring (pressure) was applied; all patients who underwent LASIK and presented a decrease in heart rate during the procedure were asymptomatic.

For the purpose of this study, we measured how many seconds it took to perform the IVI. For the experienced ophthalmologist, IVI took 10 seconds or less, in contrast with rectus muscle traction during strabismus surgery (minutes) \[[@B55], [@B56]\].
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OCR has been reported in 14% to 90% of patients during strabismus surgery \[[@B57]\]. Although OCR has been described in adult patients during different ophthalmological procedures \[[@B13], [@B20], [@B58]\], it is more common in children. Muscle traction during strabismus surgery and muscle entrapment in blowout fractures \[[@B59]-[@B62]\] of the orbit are the two most common circumstances associated with OCR. Individual cases of OCR during different procedures in adults under local anesthesia could be seen as anecdotal, but the ophthalmologist must be aware of its possible occurrence.

We assume that in this study OCR was asymptomatic because of the short duration of the procedure \[[@B63]-[@B65]\]. The "2018 Update on Intravitreal Injections: Euretina Consensus Recommendations" addresses important issues related to pre-injection, peri-injection and post-injection management \[[@B45]\]. The authors stated that "the ophthalmologist should be aware of the potential cardiovascular and cerebrovascular risks of these agents". Unusual systemic events after anti-VEGF IVIs have been reported, such as visual hallucinations, erectile dysfunction and acute decrease in kidney function \[[@B45]\] The role of anti-VEGF in these instances remains to be established.

After a comprehensive PubMed search, we could not find any report in the literature concerning OCR and IVI. This is because heart rate is not monitored during IVI and therefore not detected. A similar situation occurred during LASIK, OCR was not considered until heart rate was monitored during the procedure \[[@B13], [@B31]\]. This is the first report of OCR during IVI. Although our study included over 500 patients, it was single center, and compromised three types IVI and three medications. Therefore, further multicentric studies with more sample size, and wide range of injected medications and indications, must be done to confirm our findings.

CONCLUSION
==========

In conclusion, OCR occurred in 3.3% of patients during IVI. Hence, OCR must be considered when performing IVIs.
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